This trial is testing a new drug for people with multiple myeloma who have relapsed or are refractory to other treatments. The goal is to see if the drug is safe and tolerable and if it has any preliminary biological or clinical activity.
- Multiple Myeloma
3 Primary · 15 Secondary · Reporting Duration: Up to approximately 2 years
1 Treatment Group
Administration of CC-92328
1 of 1
70 Total Participants · 1 Treatment Group
Primary Treatment: CC-92328 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What are the objectives of this scientific experiment?
"The primary objective of this clinical trial, which will be monitored within a 12 week window after the final dose is administered, is to ascertain Maximum Tolerated Dose (MTD). Secondary endpoints being evaluated include Total body clearance of drug from serum (Pharmacokinetics - CL), Overall Survival (Time taken for death due to any cause post first CC-92328 dosage) and Area under Curve analysis." - Anonymous Online Contributor
Are there a range of medical centers conducting this investigation within city limits?
"This study is being conducted in numerous locations across the world, such as University Of Alabama At Birmingham Hospital in Birmingham, Local Institution - 203 in Halifax, and Local Institution - 205 in Montreal. Altogether 17 sites are participating." - Anonymous Online Contributor
How risk-free is CC-92328 for individuals?
"Due to the limited data supporting efficacy and safety, CC-92328 was assigned a score of 1 on our team's risk assessment scale." - Anonymous Online Contributor
What is the capacity for participants in this investigation?
"To conclude this clinical trial, the sponsor Celgene needs to recruit 70 qualified participants from multiple sites such as University Of Alabama At Birmingham Hospital in Birmingham and Local Institution - 203 in Halifax." - Anonymous Online Contributor
Are there still openings available for this clinical experiment?
"Correct. The details hosted on clinicaltrials.gov demonstrate that this research, which was initially posted on October 5th 2021, is still in need of participants. Seventy individuals are needed to be recruited from 17 physical trial centres." - Anonymous Online Contributor